<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03413514</url>
  </required_header>
  <id_info>
    <org_study_id>2017YJZ51</org_study_id>
    <nct_id>NCT03413514</nct_id>
  </id_info>
  <brief_title>Real World Evidence for the Cycle of Neoadjuvant Chemotherapy in Gastric Cancer With Shared Decision Making</brief_title>
  <acronym>RECOMMEND</acronym>
  <official_title>A Non-Randomized,Single Center Study to Investigate the Real World Evidence for the Maximal Cycle of Effective Neoadjuvant Chemotherapy in Gastric Cancer With Shared Decision Making</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the maximal cycle of effective neoadjuvant
      chemotherapy for resectable gastric cancer, to determine what is the best cycle of
      neoadjuvant chemotherapy for the patients who receive neoadjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a non-randomized clinical trial. The protocol has been approved by the Ethics
      Committee of Beijing Cancer Hospital. MRI and enhanced CT are used to evaluate the clinical
      response of the tumor. The primary endpoint is the maximal cycle of effective neoadjuvant
      chemotherapy for resectable gastric cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2018</start_date>
  <completion_date type="Anticipated">January 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 3, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The cycle of neoadjuvant chemotherapy</measure>
    <time_frame>18months</time_frame>
    <description>The cycle of neoadjuvant chemotherapy means the maximal cycle of effective neoadjuvant chemotherapy. The effective means no disease progress by image diagnosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The clinical response rate</measure>
    <time_frame>18 months</time_frame>
    <description>The clinical response is evaluated by CT/MRI according to the Response Evaluation Criteria In Solid Tumors (RECIST)1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The completion rate of perioperative chemotherapy</measure>
    <time_frame>18 months</time_frame>
    <description>The completion rate of perioperative chemotherapy means the patient completed the 8 cycles of perioperative chemotherapy as planned (n cycles of neoadjuvant chemotherapy and 8-n cycles of adjuvant chemotherapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The progressive disease rate</measure>
    <time_frame>18 months</time_frame>
    <description>The progressive disease during neoadjuvant chemotherapy with shared decision making is is evaluated by CT/MRI according to the Response Evaluation Criteria In Solid Tumors (RECIST)1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pathological response</measure>
    <time_frame>18 months</time_frame>
    <description>The pathological response during neoadjuvant chemotherapy with shared decision making is evaluated according to the tumor regression grade of NCCN guideline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pathological complete response</measure>
    <time_frame>18months</time_frame>
    <description>The pathological complete response is defined as ypT0N0M0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The adverse event of chemotherapy</measure>
    <time_frame>18 months</time_frame>
    <description>The adverse event of chemotherapy is evaluated and recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) v.3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical morbidity</measure>
    <time_frame>18 months</time_frame>
    <description>Surgical morbidity is defined as the events which occurs with-in postoperative 30 days, extension of hospitalization and re-hospitalization. It is necessary to evaluate the complication and if it occurs during the hospitalization, it is required to record complication name, date of on-set (postoperatively), grade on Clavien-Dindo Classification and treatment for complication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 3-year progression-free survival</measure>
    <time_frame>48months</time_frame>
    <description>In terms of locally advanced gastric cancer, to evaluate the progression-free survival rate in gastrectomy with D2 lymph node dissection at postoperative 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cTNM,ycTNM,ypTNM stage</measure>
    <time_frame>60months</time_frame>
    <description>The cTNM stage, ycTNM stage and ypTNM stage is defined according to the 8th TNM stage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The decisional conflicts</measure>
    <time_frame>12months</time_frame>
    <description>The decisional conflicts is evaluated by Decisional Conflict Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The decisional regrets</measure>
    <time_frame>12months</time_frame>
    <description>The decisional regrets is evaluated by Decision Regret Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The involvement of patients during the shared decision making</measure>
    <time_frame>12months</time_frame>
    <description>The involvement of patients during the shared decision making is evaluated by MAPPIN'SDM questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>experiment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy(NACT) are performed for locally advanced gastric cancer. The clinical response is evaluated by MRI and enhanced CT. The cycle of neoadjuvant chemotherapy is decided by the doctor and the patents together with shared decision making(SDM). Radical gastrectomy with D2 lymph node dissection are performed after neoadjuvant chemotherapy. Adjuvant chemotherapy(ACT) are preformed after surgery. Questionnaires are preformed to evaluate the involvement emotion and reason for the decision of stopping neoadjuvant chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NACT</intervention_name>
    <description>SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for n courses.(0&lt;n&lt;8)</description>
    <arm_group_label>experiment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SDM</intervention_name>
    <description>Making the decision about the cycle of neoadjuvant chemotherapy with shared decision making</description>
    <arm_group_label>experiment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Radical surgery with D2 lymph node dissection</description>
    <arm_group_label>experiment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT</intervention_name>
    <description>SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for 8-n courses.(0&lt;n&lt;8)</description>
    <arm_group_label>experiment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>MAPPIN'SDM questionnaire, the control performance card, the care questionnaire, the decisional conflict questionnaire, the decisional regret questionnaire, the questionnaire of the reason for stopping neoadjuvant chemotherapy</description>
    <arm_group_label>experiment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven adenocarcinoma of the stomach

          2. Clinical cT2N+M0,or cT3-4a/N+M0 disease, confirmed by upper gastrointestinal endoscopy
             and abdominal computed tomography (CT) and MRI and laparoscopy.

          3. Receive neoadjuvant chemotherapy in clinical

        Exclusion Criteria:

          1. Contraindication for chemotherapy

          2. Contraindication for surgery

          3. Clinically apparent distant metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ziyu Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Cancer Hospital &amp; Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiafu Ji, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Cancer Hospital &amp; Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ziyu Li, MD</last_name>
    <phone>86-010-8819-6605</phone>
    <email>ligregory@outlook.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yinkui Wang, MD</last_name>
    <phone>86-010-88196598</phone>
    <email>wykchangfeng@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziyu Li, M.D.</last_name>
      <phone>86-010-8819-6605</phone>
      <email>ligregory@outlook.com</email>
    </contact>
    <contact_backup>
      <last_name>Yinkui Wang, M.D.</last_name>
      <phone>86-010-8819-6598</phone>
      <email>wykchangfeng@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ziyu Li, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fei Shan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yinkui Wang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shuangxi Li, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yongning Jia, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hui Ren, M.M.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yingai Li, M.B.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiangji Ying, M.S., M.P.H.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fei Pang, M.M.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiafu Ji, M.D., P.H.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.</citation>
    <PMID>25651787</PMID>
  </reference>
  <reference>
    <citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.</citation>
    <PMID>26808342</PMID>
  </reference>
  <reference>
    <citation>Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017 Jan;20(1):1-19. doi: 10.1007/s10120-016-0622-4. Epub 2016 Jun 24.</citation>
    <PMID>27342689</PMID>
  </reference>
  <reference>
    <citation>Yoshikawa T, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, Hirabayashi N, Mikata S, Iwahashi M, Fukushima R, Takiguchi N, Miyashiro I, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J. Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial. Ann Surg Oncol. 2014 Jan;21(1):213-9. doi: 10.1245/s10434-013-3055-x. Epub 2013 Jul 10.</citation>
    <PMID>23838904</PMID>
  </reference>
  <reference>
    <citation>Aoyama T, Nishikawa K, Fujitani K, Tanabe K, Ito S, Matsui T, Miki A, Nemoto H, Sakamaki K, Fukunaga T, Kimura Y, Hirabayashi N, Yoshikawa T. Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer. Ann Oncol. 2017 Aug 1;28(8):1876-1881. doi: 10.1093/annonc/mdx236.</citation>
    <PMID>28486692</PMID>
  </reference>
  <reference>
    <citation>Schulz C, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, Stauder H, Wein A, Al-Batran SE, Kubin T, Sch√§fer C, Stintzing S, Giessen C, Modest DP, Ridwelski K, Heinemann V. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. Int J Cancer. 2015 Aug 1;137(3):678-85. doi: 10.1002/ijc.29403. Epub 2015 Feb 25.</citation>
    <PMID>25530271</PMID>
  </reference>
  <reference>
    <citation>Kane HL, Halpern MT, Squiers LB, Treiman KA, McCormack LA. Implementing and evaluating shared decision making in oncology practice. CA Cancer J Clin. 2014 Nov-Dec;64(6):377-88. doi: 10.3322/caac.21245. Epub 2014 Sep 8. Review.</citation>
    <PMID>25200391</PMID>
  </reference>
  <reference>
    <citation>Fried TR. Shared Decision Making--Finding the Sweet Spot. N Engl J Med. 2016 Jan 14;374(2):104-6. doi: 10.1056/NEJMp1510020.</citation>
    <PMID>26760081</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2018</study_first_submitted>
  <study_first_submitted_qc>January 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Ziyu Li</investigator_full_name>
    <investigator_title>Chief Physician, Professor</investigator_title>
  </responsible_party>
  <keyword>shared decision making</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>cycle</keyword>
  <keyword>MRI</keyword>
  <keyword>clinical response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

